nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.02.2013 | Original Paper

Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol

verfasst von: Ina Giegling, Beatrice Balzarro, Stefano Porcelli, Martin Schäfer, Annette M. Hartmann, Marion Friedl, Bettina Konte, Philipp Krämer, Hans-Jürgen Möller, Diana De Ronchi, Hans H. Stassen, Alessandro Serretti, Dan Rujescu

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The present study explores whether ankyrin repeat and kinase domain containing 1 (ANKK1) and dopamine receptor D2 (DRD2) variants could predict efficacy and tolerability of haloperidol in the treatment of psychotic patients. We also attempted to replicate findings in a group of schizophrenic patients from the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) study. Eighty-eight acutely psychotic patients were genotyped for 9 ANKK1 and 27 DRD2 SNPs. Treatment efficacy and tolerability were assessed using the Positive and Negative Symptoms Scale and the Udvalg for Kliniske Undersogelser side effects rating scales, respectively. Multivariate analyses were employed to test possible influences of single-nucleotide polymorphisms on clinical and safety variables. Analysis of haplotypes was also performed. Outcomes in the replication sample were response versus nonresponse and the presence versus absence of motor side effects at 1 month of treatment. rs2242592 within ANKK1 gene and rs1124493 within DRD2 gene were associated with clinical improvement (p = 0.008 and p = 0.001, respectively). Results were confirmed in the allelic analysis. Three haplotype blocks, one among ANKK1 and two among DRD2 gene were associated with better clinical improvement. Our results were not replicated in the CATIE sample, although rs11604671, which is in strong linkage disequilibrium with rs2242592, was associated with response in the replication sample. Our findings support a possible role of ANKK1 and DRD2 variability on haloperidol efficacy. However, due to the discrepancies between the results in the two samples, our results need further validation.

Nur mit Berechtigung zugänglich

Tandon R, Keshavan MS, Nasrallah HA (2008) Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102(1–3):1–18PubMedCrossRef

Lennertz L, Quednow BB, Benninghoff J, Wagner M, Maier W, Mossner R (2011) Impact of TCF4 on the genetics of schizophrenia. Eur Arch Psychiatry Clin Neurosci 261(Suppl 2):S161–S165PubMedCrossRef

Arranz MJ, Rivera M, Munro JC (2010) Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25(11):933–969CrossRef

Crisafulli C, Chiesa A, Han C, Lee SJ, Park MH, Balzarro B, Andrisano C, Patkar AA, Pae CU, Serretti A (2011) Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur Arch Psychiatry Clin Neurosci 262(3):199–205

Mossner R, Schuhmacher A, Wagner M, Lennertz L, Steinbrecher A, Quednow BB, Rujescu D, Rietschel M, Maier W (2011) The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. Eur Arch Psychiatry Clin Neurosci 262(3):193–197

Tiwari AK, Zai CC, Muller DJ, Kennedy JL (2010) Genetics in schizophrenia: where are we and what next? Dialogues Clin Neurosci 12(3):289–303PubMed

Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6(4):577–582PubMedCrossRef

Jonsson EG, Nothen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M, Asberg M, Propping P, Sedvall GC (1999) Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 40(1):31–36PubMedCrossRef

Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L (2005) Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 376(1):1–4PubMedCrossRef

10.

Malhotra AK (2004) Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain. Neurotox Res 6(1):51–56PubMedCrossRef

11.

Tanaka T, Igarashi S, Onodera O, Tanaka H, Fukushima N, Takahashi M, Kameda K, Tsuji S, Ihda S (1996) Lack of association between dopamine D2 receptor gene Cys311 variant and schizophrenia. Am J Med Genet 67(2):208–211PubMedCrossRef

12.

Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH (2004) Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol (CINP) 7(4):461–470CrossRef

13.

Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R (1994) DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343(8904):1045–1046PubMed

14.

Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205–216PubMedCrossRef

15.

Hirvonen J, Aalto S, Lumme V, Nagren K, Kajander J, Vilkman H, Hagelberg N, Oikonen V, Hietala J (2003) Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride. Nucl Med Commun 24(12):1207–1214PubMedCrossRef

16.

Lawford BR, Young RM, Swagell CD, Barnes M, Burton SC, Ward WK, Heslop KR, Shadforth S, van Daal A, Morris CP (2005) The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia. Schizophr Res 73(1):31–37PubMedCrossRef

17.

Monakhov M, Golimbet V, Abramova L, Kaleda V, Karpov V (2008) Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population. Schizophr Res 100(1–3):302–307PubMedCrossRef

18.

Ponce G, Perez-Gonzalez R, Aragues M, Palomo T, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J (2009) The ANKK1 kinase gene and psychiatric disorders. Neurotox Res 16(1):50–59PubMedCrossRef

19.

Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Otani K, Furukori H, Kaneko S, Inoue Y (2001) Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. Eur Arch Psychiatry Clin Neurosci 251(2):57–59PubMedCrossRef

20.

Noble EP (2003) D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 116B(1):103–125PubMedCrossRef

21.

Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J (1998) Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 155(6):768–773PubMed

22.

Thompson TL, Moss RL (1997) Modulation of mesolimbic dopaminergic activity over the rat estrous cycle. Neurosci Lett 229(3):145–148PubMedCrossRef

23.

Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Moller HJ (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 158(5):802–804PubMedCrossRef

24.

Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, Luu SU (2009) Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 43(6):600–606PubMedCrossRef

25.

Suzuki A, Kondo T, Mihara K, Furukori H, Nagashima U, Ono S, Otani K, Kaneko S (2000) Association between Taq1 a dopamine D2 receptor polymorphism and psychopathology of schizophrenia in Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 24(7):1105–1113PubMedCrossRef

26.

Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N (2003) Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 3(6):356–361PubMedCrossRef

27.

Neville MJ, Johnstone EC, Walton RT (2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23(6):540–545PubMedCrossRef

28.

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29(1):15–31PubMedCrossRef

29.

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276PubMedCrossRef

30.

Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334:1–100CrossRef

31.

Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S (2009) Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res 113(1):34–40PubMedCrossRef

32.

Obermeier M, Schennach-Wolff R, Meyer S, Moller HJ, Riedel M, Krause D, Seemuller F (2011) Is the PANSS used correctly? A systematic review. BMC Psychiatry 11:113PubMedCrossRef

33.

Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G (2005) Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res 77(2–3):119–128PubMedCrossRef

34.

Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676PubMedCrossRef

35.

Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19CrossRef

36.

Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D (2009) Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol (Clifton, NJ) 578:307–343CrossRef

37.

Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, Swan GE, Rutter J, Bertelsen S, Fox L, Fugman D, Goate AM, Hinrichs AL, Konvicka K, Martin NG, Montgomery GW, Saccone NL, Saccone SF, Wang JC, Chase GA, Rice JP, Ballinger DG (2007) Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16(1):24–35PubMedCrossRef

38.

Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13(6):570–584PubMedCrossRef

39.

Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125(1–2):279–284PubMedCrossRef

40.

Barrett JC (2009) Haploview: visualization and analysis of SNP genotype data. Cold Spring Harbor protocols 2009 (10): pdb ip71

41.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559–575PubMedCrossRef

42.

Dubertret C, Bardel C, Ramoz N, Martin PM, Deybach JC, Ades J, Gorwood P, Gouya L (2010) A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Prog Neuropsychopharmacol Biol Psychiatry 34(3):492–499PubMedCrossRef

43.

Houston J, Dharia S, Bishop JR, Ellingrod VL, Fijal B, Jacobson JG, Hoffmann VP (2011) Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res 187(1–2):74–79PubMedCrossRef

44.

Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN (2012) Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One 7(5):e36561PubMedCrossRef

45.

Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, Malhotra AK (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 20(9):569–572PubMedCrossRef

46.

Cordeiro Q, Siqueira-Roberto J, Zung S, Vallada H (2009) Association between the DRD2-141C insertion/deletion polymorphism and schizophrenia. Arq Neuropsiquiatr 67(2A):191–194PubMedCrossRef

47.

Parsons MJ, Mata I, Beperet M, Iribarren-Iriso F, Arroyo B, Sainz R, Arranz MJ, Kerwin R (2007) A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate. Psychiatr Genet 17(3):159–163PubMedCrossRef

48.

Sullivan PF (2007) Spurious genetic associations. Biol Psychiatry 61(10):1121–1126PubMedCrossRef

Titel: Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol
verfasst von: Ina Giegling
Beatrice Balzarro
Stefano Porcelli
Martin Schäfer
Annette M. Hartmann
Marion Friedl
Bettina Konte
Philipp Krämer
Hans-Jürgen Möller
Diana De Ronchi
Hans H. Stassen
Alessandro Serretti
Dan Rujescu
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 1/2013
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-012-0348-1

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia

A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients

Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence

The DTNBP1 (dysbindin-1) gene variant rs2619522 is associated with variation of hippocampal and prefrontal grey matter volumes in humans

Changes in cortical thickness in the frontal lobes in schizophrenia are a result of thinning of pyramidal cell layers

Schizophrenia: brain morphology and treatment aspects

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie